Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.

PubWeight™: 3.93‹?› | Rank: Top 1%

🔗 View Article (PMID 32199095)

Published in Lancet Neurol on March 18, 2020

Authors

Masayuki Tahara1, Tomoko Oeda2, Kazumasa Okada3, Takao Kiriyama4, Kazuhide Ochi5, Hirofumi Maruyama5, Hikoaki Fukaura6, Kyoichi Nomura6, Yuko Shimizu7, Masahiro Mori8, Ichiro Nakashima9, Tatsuro Misu10, Atsushi Umemura2, Kenji Yamamoto2, Hideyuki Sawada2

Author Affiliations

1: Clinical Research Centre and Department of Neurology, National Hospital Organization Utano National Hospital, Kyoto, Japan. Electronic address: tahara.masayuki.ne@mail.hosp.go.jp.
2: Clinical Research Centre and Department of Neurology, National Hospital Organization Utano National Hospital, Kyoto, Japan.
3: Department of Neurology, University of Occupational and Environmental Health, Kitakyushu, Japan.
4: Department of Neurology, Nara Medical University School of Medicine, Nara, Japan.
5: Department of Clinical Neuroscience and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
6: Department of Neurology, Saitama Medical University, Kawagoe, Japan.
7: Department of Neurology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
8: Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.
9: Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
10: Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Articles by these authors

Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD. Acta Neuropathol Commun (2016) 0.90

Different electrophysiological profiles and treatment response in 'typical' and 'atypical' chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry (2014) 0.87

Seronegative neuromyelitis optica spectrum disorder patients diagnosed using new diagnostic criteria. Mult Scler (2015) 0.83

Steroid-Responsive Epilepsia Partialis Continua with Anti-Thyroid Antibodies: A Spectrum of Hashimoto's Encephalopathy? Case Rep Neurol (2014) 0.79

Epstein-Barr virus persistence and reactivation in neuromyelitis optica. J Neurol Neurosurg Psychiatry (2014) 0.79

Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood-brain barrier disruption. Mult Scler (2016) 0.76

Lower motor neuron syndrome associated with IgG anti-GM1 antibodies revisited. J Neuroimmunol (2014) 0.76

Paranodal destruction and axo-glial dysjunction in a subtype of CIDP with anticontaction-1 antibodies. J Neurol Neurosurg Psychiatry (2015) 0.75

Are more sphingosine 1-phosphate receptor agonists a better therapeutic option against multiple sclerosis? J Neurol Neurosurg Psychiatry (2014) 0.75

Japanese cases of neuromyelitis optica spectrum disorder associated with myasthenia gravis and a review of the literature. Clin Neurol Neurosurg (2014) 0.75

Comparison of cognitive and brain grey matter volume profiles between multiple sclerosis and neuromyelitis optica spectrum disorder. PLoS One (2017) 0.75

Trigeminal root entry zone involvement in neuromyelitis optica and multiple sclerosis. J Neurol Sci (2015) 0.75

Nodopathy: chronic inflammatory demyelinating polyneuropathy with anti-neurofascin 155 antibodies. J Neurol Neurosurg Psychiatry (2017) 0.75

A case of fulminant neuromyelitis optica presenting with destructive lesions in whole-brain. Clin Neurol Neurosurg (2013) 0.75

Benign neuromyelitis optica is rare in Japanese patients. Mult Scler (2014) 0.75

Levels of nitric oxide metabolites in cerebrospinal fluid correlate with cognitive impairment in early stage multiple sclerosis. J Neurol Neurosurg Psychiatry (2017) 0.75

[Clinical features of NMO according to brain MRI findings]. Brain Nerve (2010) 0.75

Geographical differences in preventative therapies for neuromyelitis optica spectrum disorder. J Neurol Neurosurg Psychiatry (2017) 0.75

Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders. Sci Rep (2020) 0.75